PCSK9 Inhibitor Coverage Often Denied for Patients With FH PCSK9 Inhibitor Coverage Often Denied for Patients With FH

Despite PCSK9 ' s approval in 2015 for FH patients not responding to statins, many are still finding access to the potentially lifesaving nonstatin lipid-lowering agents a challenge.Heartwire from Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news